Faculty

Back to Index
Tanya Dorff, MD
Assistant Professor of Clinical Medicine
Medicine
NOR 3457 Health Sciences Campus Los Angeles
+1 323 865 3905

Overview

Following a residency at Mt. Sinai Hospital in New York City, Dr. Dorff came to LAC+USC Medical Center on a hematology and medical oncology fellowship. She currently teaches in the Division of Oncology at the Keck School of Medicine of USC. In addition to being a devoted clinician and researcher, Dr. Dorff has authored numerous published articles and serves as a reviewer for many journals, including Cancer and Current Cancer Drug Targets. She has lectured on the topic of prostate cancer, both in English and in Spanish, across California and has been either the principal or co-investigator on a dozen clinical trials.

Awards

AUA Western Section Best Poster: 3rd Place, 2010

Faculty Teaching Award

Fellowship Teaching Award

Medical Honors Society: AOA - Alpha Omega Alpha, 2000

AMWA Janet M. Glasgow Memorial: Achievement Citation, 2000

ACP/ASIM James R. Klinenberg: Certificate of Merit, 2000

National Merit Scholar

Keck School of Medicine of USC: Faculty Teaching Award, 2014

Keck School of Medicine of USC: Faculty Teaching Award, 2010

Publications

Dorff TB, Schuckman AK, Schwartz R, Rashad S, Bulbul A, Cai J, Pinski J, Ma Y, Danenberg K, Skinner E, Quinn DI. Epidermal Growth Factor Receptor, Excision-Repair Cross-Complementation Group 1 Protein, and Thymidylate Synthase Expression in Penile Cancer. Clin Genitourin Cancer. 2016 Oct; 14(5):450-456. e1. View in: PubMed

Rini BI, Dorff TB, Elson P, Rodriguez CS, Shepard D, Wood L, Humbert J, Pyle L, Wong YN, Finke JH, Rayman PA, Larkin JM, Garcia JA, Plimack ER. Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trial. Lancet Oncol. 2016 Sep; 17(9):1317-24. View in: PubMed

Feldman DR, Hu J, Dorff TB, Lim K, Patil S, Woo KM, Carousso M, Hughes A, Sheinfeld J, Bains M, Daneshmand S, Ketchens C, Bajorin DF, Bosl GJ, Quinn DI, Motzer RJ. Paclitaxel, Ifosfamide, and Cisplatin Efficacy for First-Line Treatment of Patients With Intermediate- or Poor-Risk Germ Cell Tumors. J Clin Oncol. 2016 Jul 20; 34(21):2478-83. View in: PubMed

Dorff TB, Groshen S, Garcia A, Shah M, Tsao-Wei D, Pham H, Cheng CW, Brandhorst S, Cohen P, Wei M, Longo V, Quinn DI. Safety and feasibility of fasting in combination with platinum-based chemotherapy. BMC Cancer. 2016; 16(1):360. View in: PubMed

Dorff TB, Hu J, Quinn DI. Relapsed and refractory germ cell tumors: Finessing the rough end of a beautiful story. Urol Oncol. 2015 Aug; 33(8):341-2. View in: PubMed

In G, Dorff T. Chemotherapy for Good-Risk Nonseminomatous Germ Cell Tumors: Current Concepts and Controversies. Urol Clin North Am. 2015 Aug; 42(3):347-57. View in: PubMed

Brandhorst S, Choi IY, Wei M, Cheng CW, Sedrakyan S, Navarrete G, Dubeau L, Yap LP, Park R, Vinciguerra M, Di Biase S, Mirzaei H, Mirisola MG, Childress P, Ji L, Groshen S, Penna F, Odetti P, Perin L, Conti PS, Ikeno Y, Kennedy BK, Cohen P, Morgan TE, Dorff TB, Longo VD. A Periodic Diet that Mimics Fasting Promotes Multi-System Regeneration, Enhanced Cognitive Performance, and Healthspan. Cell Metab. 2015 Jul 7; 22(1):86-99. View in: PubMed

Dorff TB, Pal SK. Hitting Prostate Cancer Where It Hurts: Maximizing Control of Osseous Metastases. Oncology (Williston Park). 2015 Jun 15; 29(6). View in: PubMed

Dorff TB, Gross ME. Radium 223: how can we optimize this new tool for metastatic castration-resistant prostate cancer? Am Soc Clin Oncol Educ Book. 2015; 35:e270-3. View in: PubMed

Liu SV, Tsao-Wei DD, Xiong S, Groshen S, Dorff TB, Quinn DI, Tai YC, Engel J, Hawes D, Schally AV, Pinski JK. Phase I, Dose-Escalation Study of the Targeted Cytotoxic LHRH Analog AEZS-108 in Patients with Castration- and Taxane-Resistant Prostate Cancer. Clin Cancer Res. 2014 Dec 15; 20(24):6277-83. View in: PubMed

Pond GR, Milowsky MI, Kolinsky MP, Eigl BJ, Necchi A, Harshman LC, Di Lorenzo G, Dorff TB, Lee RJ, Sonpavde G. Concurrent chemoradiotherapy for men with locally advanced penile squamous cell carcinoma. Clin Genitourin Cancer. 2014 Dec; 12(6):440-6. View in: PubMed

Piatek CI, Raja GL, Ji L, Gitlitz BJ, Dorff TB, Quinn DI, Hu J, El-Khoueiry AB, Pham HQ, Roman L, Garcia AA. Phase I clinical trial of temsirolimus and vinorelbine in advanced solid tumors. Cancer Chemother Pharmacol. 2014 Dec; 74(6):1227-34. View in: PubMed

Agarwal N, Dorff T, Goldkorn A. New prostate cancer drugs: extending and improving life. Lancet Oncol. 2014 Sep; 15(10):1052-4. View in: PubMed

Cheng CW, Adams GB, Perin L, Wei M, Zhou X, Lam BS, Da Sacco S, Mirisola M, Quinn DI, Dorff TB, Kopchick JJ, Longo VD. Prolonged Fasting Reduces IGF-1/PKA to Promote Hematopoietic-Stem-Cell-Based Regeneration and Reverse Immunosuppression. Cell Stem Cell. 2014 Jun 5; 14(6):810-23. View in: PubMed

Dorff TB, Hu JS, Quinn DI. Salvage chemotherapy for refractory germ cell tumors. Oncology (Williston Park). 2014 Jun; 28(6):498-500. View in: PubMed

Pond GR, Di Lorenzo G, Necchi A, Eigl BJ, Kolinsky MP, Chacko RT, Dorff TB, Harshman LC, Milowsky MI, Lee RJ, Galsky MD, Federico P, Bolger G, Deshazo M, Mehta A, Goyal J, Sonpavde G. Prognostic risk stratification derived from individual patient level data for men with advanced penile squamous cell carcinoma receiving first-line systemic therapy. Urol Oncol. 2014 May; 32(4):501-8. View in: PubMed

Jayaratna IS, Mitra AP, Schwartz RL, Dorff TB, Schuckman AK. Clinicopathologic Characteristics and Outcomes of Penile Cancer Treated at Tertiary Care Centers in the Western United States. Clin Genitourin Cancer. 2014 Apr; 12(2):138-42. View in: PubMed

Dorff TB, Wilkins C, Hepgur M, Quinn DI. Durable complete remission from castration-resistant prostate cancer with sipuleucel-T after estrogen withdrawal. Clin Genitourin Cancer. 2014 Apr; 12(2):e55-8. View in: PubMed

Brown A, Ma Y, Danenberg K, Schuckman AK, Pinski JK, Pagliaro LC, Quinn DI, Dorff TB. Epidermal Growth Factor Receptor-targeted Therapy in Squamous Cell Carcinoma of the Penis: A Report of 3 Cases. Urology. 2014 Jan; 83(1):159-66. View in: PubMed

Mitra AP, Skinner EC, Schuckman AK, Quinn DI, Dorff TB, Daneshmand S. Effect of gender on outcomes following radical cystectomy for urothelial carcinoma of the bladder: A critical analysis of 1,994 patients. Urol Oncol. 2014 Jan; 32(1):52. e1-9. View in: PubMed

Vashistha V, Quinn DI, Dorff TB, Daneshmand S. Current and recent clinical trials for perioperative systemic therapy for muscle invasive bladder cancer: a systematic review. BMC Cancer. 2014; 14:966. View in: PubMed

Dorff TB, Pal SK, Quinn DI. Novel tyrosine kinase inhibitors for renal cell carcinoma. Expert Rev Clin Pharmacol. 2014 Jan; 7(1):67-73. View in: PubMed

Dorff TB, Tsao-Wei DD, Groshen S, Boswell W, Goldkorn A, Xiong S, Quinn DI, Pinski JK. Efficacy of oxaliplatin plus pemetrexed in chemotherapy pretreated metastatic castration-resistant prostate cancer. Clin Genitourin Cancer. 2013 Dec; 11(4):416-22. View in: PubMed

Fairey AS, Daneshmand S, Quinn D, Dorff T, Dorin R, Lieskovsky G, Schuckman A, Cai J, Miranda G, Skinner EC. Neoadjuvant chemotherapy with gemcitabine/cisplatin vs. methotrexate/vinblastine/doxorubicin/cisplatin for muscle-invasive urothelial carcinoma of the bladder: A retrospective analysis from the University of Southern California. Urol Oncol. 2013 Nov; 31(8):1737-43. View in: PubMed

Jadvar H, Desai B, Ji L, Conti PS, Dorff TB, Groshen SG, Pinski JK, Quinn DI. Baseline 18F-FDG PET/CT parameters as imaging biomarkers of overall survival in castrate-resistant metastatic prostate cancer. J Nucl Med. 2013 Aug; 54(8):1195-201. View in: PubMed

Dorff TB, Wong MK. Weighing the evidence for immune therapy and targeted therapy in renal cancer and melanoma. Oncology (Williston Park). 2013 Jul; 27(7):691-2, 694. View in: PubMed

Dorff TB, Glode LM. Current role of neoadjuvant and adjuvant systemic therapy for high-risk localized prostate cancer. Curr Opin Urol. 2013 Jul; 23(4):366-71. View in: PubMed

Hepgur M, Sadeghi S, Dorff TB, Quinn DI. Tivozanib in the treatment of renal cell carcinoma. Biologics. 2013; 7:139-48. View in: PubMed

Fahed E, Hansel DE, Raghavan D, Quinn DI, Dorff TB. Small cell bladder cancer: biology and management. Semin Oncol. 2012 Oct; 39(5):615-8. View in: PubMed

Jadvar H, Desai B, Ji L, Conti PS, Dorff TB, Groshen SG, Gross ME, Pinski JK, Quinn DI. Prospective Evaluation of 18F-NaF and 18F-FDG PET/CT in Detection of Occult Metastatic Disease in Biochemical Recurrence of Prostate Cancer. Clin Nucl Med. 2012 Jul; 37(7):637-43. View in: PubMed

Zhang SY, Thara E, Quinn D, Dorff T. Blood cells and their use in active immunotherapy of prostate cancer. Hum Vaccin Immunother. 2012 Apr 1; 8(4):528-33. View in: PubMed

Mitra AP, Quinn DI, Dorff TB, Skinner EC, Schuckman AK, Miranda G, Gill IS, Daneshmand S. Factors influencing post-recurrence survival in bladder cancer following radical cystectomy. BJU Int. 2012 Mar; 109(6):846-54. View in: PubMed

Thara E, Dorff TB, Averia-Suboc M, Luther M, Reed ME, Pinski JK, Quinn DI. Immune response to sipuleucel-T in prostate cancer. Cancers (Basel). 2012; 4(2):420-41. View in: PubMed

Dorff TB, Liu SV, Xiong S, Cai J, Hawes D, Pinski J. Ethnic differences in neuroendocrine expression in prostate cancer tissue. Anticancer Res. 2011 Nov; 31(11):3897-901. View in: PubMed

Thara E, Dorff TB, Pinski JK, Quinn DI. Vaccine therapy with sipuleucel-T (Provenge) for prostate cancer. Maturitas. 2011 Aug; 69(4):296-303. View in: PubMed

Dorff TB, Vogelzang NJ. Use of testosterone replacement therapy in patients with prostate cancer. Curr Urol Rep. 2011 Jun; 12(3):223-8. View in: PubMed

Dorff TB, Flaig TW, Tangen CM, Hussain MH, Swanson GP, Wood DP, Sakr WA, Dawson NA, Haas NB, Crawford ED, Vogelzang NJ, Thompson IM, Glode LM. Adjuvant androgen deprivation for high-risk prostate cancer after radical prostatectomy: SWOG S9921 study. J Clin Oncol. 2011 May 20; 29(15):2040-5. View in: PubMed

Dorff TB, Pinski J. Advanced prostate cancer: new agents, new questions. Oncology (Williston Park). 2011 May; 25(6):509, 512. View in: PubMed

Dorff TB, Gross ME. The epothilones: new therapeutic agents for castration-resistant prostate cancer. Oncologist. 2011; 16(10):1349-58. View in: PubMed

Raffaghello L, Safdie F, Bianchi G, Dorff T, Fontana L, Longo VD. Fasting and differential chemotherapy protection in patients. Cell Cycle. 2010 Nov 15; 9(22):4474-6. View in: PubMed

Mori R, Dorff TB, Xiong S, Tarabolous CJ, Ye W, Groshen S, Danenberg KD, Danenberg PV, Pinski JK. The relationship between proangiogenic gene expression levels in prostate cancer and their prognostic value for clinical outcomes. Prostate. 2010 Nov 1; 70(15):1692-700. View in: PubMed

Dorff TB, Quinn DI. Cabazitaxel in prostate cancer: stretching a string. Lancet. 2010 Oct 2; 376(9747):1119-20. View in: PubMed

DeSancho MT, Dorff T, Rand JH. Thrombophilia and the risk of thromboembolic events in women on oral contraceptives and hormone replacement therapy. Blood Coagul Fibrinolysis. 2010 Sep; 21(6):534-8. View in: PubMed

Dorff TB, Goldman B, Pinski JK, Mack PC, Lara PN, Van Veldhuizen PJ, Quinn DI, Vogelzang NJ, Thompson IM, Hussain MH. Clinical and correlative results of SWOG S0354: a phase II trial of CNTO328 (siltuximab), a monoclonal antibody against interleukin-6, in chemotherapy-pretreated patients with castration-resistant prostate cancer. Clin Cancer Res. 2010 Jun 1; 16(11):3028-34. View in: PubMed

Leibowitz RL, Dorff TB, Tucker S, Symanowski J, Vogelzang NJ. Testosterone replacement in prostate cancer survivors with hypogonadal symptoms. BJU Int. 2010 May; 105(10):1397-401. View in: PubMed

Safdie FM, Dorff T, Quinn D, Fontana L, Wei M, Lee C, Cohen P, Longo VD. Fasting and cancer treatment in humans: A case series report. Aging (Albany NY). 2009 Dec; 1(12):988-1007. View in: PubMed

Dorff TB, Quinn DI. Perioperative chemotherapy for urothelial cancer: how have we made a "sow's ear" out of a chemotherapy-sensitive tumor? Cancer. 2009 Nov 15; 115(22):5139-42. View in: PubMed

Dorff TB, Goldkorn A, Quinn DI. Targeted therapy in renal cancer. Ther Adv Med Oncol. 2009 Nov; 1(3):183-205. View in: PubMed

Sunami E, Shinozaki M, Higano CS, Wollman R, Dorff TB, Tucker SJ, Martinez SR, Mizuno R, Singer FR, Hoon DS. Multimarker circulating DNA assay for assessing blood of prostate cancer patients. Clin Chem. 2009 Mar; 55(3):559-67. View in: PubMed

Dorff TB, Tsao-Wei D, Miranda G, Skinner DG, Stein JP, Quinn DI. Adjuvant chemotherapy for locally advanced urothelial carcinoma: an overview of the USC experience. World J Urol. 2009 Feb; 27(1):39-44. View in: PubMed

Cheung E, Pinski J, Dorff T, Groshen S, Quinn DI, Reynolds CP, Maurer BJ, Lara PN, Tsao-Wei DD, Twardowski P, Chatta G, McNamara M, Gandara DR. Oral fenretinide in biochemically recurrent prostate cancer: a California cancer consortium phase II trial. Clin Genitourin Cancer. 2009 Jan; 7(1):43-50. View in: PubMed

Dorff TB, Tangen CM, Crawford ED, Petrylak DP, Higano CS, Raghavan D, Quinn DI, Vogelzang NJ, Thompson IM, Hussain MH. COOPERATIVE GROUP TRIALS - SOUTHWEST ONCOLOGY GROUP (SWOG) INNOVATIONS IN ADVANCED PROSTATE CANCER. Ther Adv Med Oncol. 2009; 1(2):69-77. View in: PubMed

Tagawa ST, Dorff TB, Rochanda L, Ye W, Boyle S, Raghavan D, Lieskovsky G, Skinner DG, Quinn DI, Liebman HA. Subclinical haemostatic activation and current surgeon volume predict bleeding with open radical retropubic prostatectomy. BJU Int. 2008 Nov; 102(9):1086-91. View in: PubMed

Cheung E, Wadhera P, Dorff T, Pinski J. Diet and prostate cancer risk reduction. Expert Rev Anticancer Ther. 2008 Jan; 8(1):43-50. View in: PubMed

Dorff TB, Shazer RL, Nepomuceno EM, Tucker SJ. Successful treatment of metastatic androgen-independent prostate carcinoma in a transsexual patient. Clin Genitourin Cancer. 2007 Jun; 5(5):344-6. View in: PubMed

Dorff TB, Quek ML, Daneshmand S, Pinski J. Evolving treatment paradigms for locally advanced and metastatic prostate cancer. Expert Rev Anticancer Ther. 2006 Nov; 6(11):1639-51. View in: PubMed

Quek ML, Daneshmand S, Rodrigo S, Cai J, Dorff TB, Groshen S, Skinner DG, Lieskovsky G, Pinski J. Prognostic significance of neuroendocrine expression in lymph node-positive prostate cancer. Urology. 2006 Jun; 67(6):1247-52. View in: PubMed

Daneshmand S, Dorff TB, Quek ML, Cai J, Pike MC, Nichols PW, Pinski J. Ethnic differences in neuroendocrine cell expression in normal human prostatic tissue. Urology. 2005 May; 65(5):1008-12. View in: PubMed

Pinski J, Dorff TB. Prostate cancer metastases to bone: pathophysiology, pain management, and the promise of targeted therapy. Eur J Cancer. 2005 Apr; 41(6):932-40. View in: PubMed

Powered bySC CTSI